Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Mars, Incorporated to acquire VCA Inc.
hand shake
The transaction is expected to complete later in 2017.
Transaction price set at around $9.1 billion

Mars, Incorporated has entered an agreement to acquire VCA Inc., which owns nearly 800 animal hospitals in the US and Canada.

Mars is set to acquire all outstanding shares of VCA for $93 per share - a total value of around $9.1 billion, which includes $1.4 billion in outstanding debt.

When the acquisition is complete VCA will operate as a distinct business unit within Mars Petcare, alongside other veterinary businesses; Banfield Pet Hospital, Bluepearl and Pet Partners. VCA will continue to be led by Bob Antin, its chief executive officer, president, chairman and founder.

Since it was founded in 1986, VCA has grown to nearly 800 veterinary hospitals with 60 diagnostic laboratories. The company operates across four divisions: veterinary services, laboratory diagnostics, imaging equipment and medical technology and pet care services.

Mars CEO Grant F Reid commented: “We are thrilled to welcome VCA to the Mars family and to our portfolio of brands and businesses around the world.

“VCA is a leader across pet health care and the opportunity we see together - for pets, pet owners, veterinarians and other pet care providers - is tremendous.

“We have great respect for VCA, with whom we share many common values and a strong commitment to pet care. Together, we will be able to provide even greater value, better service and higher quality care to pets and pet owners.”

The transaction is subject to VCA shareholder approval, customary regulatory approval, and other conditions. It is expected to complete later in 2017.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.